Q4 2025 Management View Leiv Lea, Chief Financial Officer, reported research and development expenses of $9.9 million in Q4 2025, attributing the increase to higher clinical trial and manufacturing ...

The trial plans to enrol around 190 women aged 18 to 45 years across seven European countries.

US-based biopharmaceutical company Spinogenix has concluded the enrolment of patients in its Phase II clinical trial of tazbentetol (previously known as SPG302), a synaptic regenerative treatment for ...

The Chinese biotech put the idea to the test in a phase 2 trial of a subcutaneous depot formulation of its GLP-1 receptor agonist ASC30. U.S. investigators randomized 65 people with obesity or who ...

Pfizer is ramping up plans for tilrekimig after a phase 2 win raised hopes that the once-monthly trispecific antibody could hold its own against approved eczema drugs. | Pfizer is ramping up plans for ...

Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 programMELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex ...

TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of ...

HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck ...